The role of gemcitabine in the treatment of malignant mesothelioma-Reference-Cited by-同舟云学术

The role of gemcitabine in the treatment of malignant mesothelioma

Published:2002-02 Issue:1 Volume:29 Page:70-76
ISSN:0093-7754
Container-title:Seminars in Oncology
language:en
Short-container-title:Seminars in Oncology

Author:

Kindler Hedy Lee,van Meerbeeck Jan.P.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference24 articles.

1. New chemotherapeutics in malignant mesothelioma: Effects on cell growth and IL-6 production;McLaren;Ca Chemother Pharmacol,2000

2. In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four new chemotherapeutic agents;Ollikainen;Anticancer Drugs,2000

3. Gemcitabine activity on murine and human malignant mesothelioma cell lines show additive activity in combination with cisplatin;Davidson;Aust NZ J Med,1997

4. A phase II study of gemcitabine in patients with malignant pleural mesothelioma;Van Meerbeeck;Cancer,1999

5. Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B;Kindler;Lung Cancer,2001

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study;ESMO Open;2022-06

2. Chemotherapeutic Protocols for the Treatment of Lung Cancer;Chemotherapy Protocols and Infusion Sequence;2022

3. Malignant Pleural Mesothelioma Interactome with 364 Novel Protein-Protein Interactions;Cancers;2021-04-01

4. Role of induction and adjuvant systemic treatment in mesothelioma: narrative review;AME Surgical Journal;2021-01

5. Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16);Annals of Oncology;2020-04